Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

141. Mood, memory, and cognition. In: Menopause and osteoporosis update 2009.

Mood, memory, and cognition. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National

2009 Society of Obstetricians and Gynaecologists of Canada

142. Urogenital health. In: Menopause and osteoporosis update 2009.

Urogenital health. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2009 Society of Obstetricians and Gynaecologists of Canada

143. Hormone therapy and breast cancer. In: Menopause and osteoporosis update 2009.

Hormone therapy and breast cancer. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding

2009 Society of Obstetricians and Gynaecologists of Canada

144. Cardiovascular disease. In: Menopause and osteoporosis update 2009.

Cardiovascular disease. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National

2009 Society of Obstetricians and Gynaecologists of Canada

145. Vasomotor symptoms. In: Menopause and osteoporosis update 2009.

Vasomotor symptoms. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2009 Society of Obstetricians and Gynaecologists of Canada

146. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety (Abstract)

Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety The objective of the study was to assess the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) for the treatment of vasomotor symptoms.This was a 26 week, double-blind, placebo-controlled trial of 567 postmenopausal women (mean age, 53.7 years; time since natural menopause, 4.8 years) experiencing 50 or more (...) only.Desvenlafaxine is an effective treatment for menopausal HFs.

2009 EvidenceUpdates Controlled trial quality: predicted high

147. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms.

NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding

2009 National Institutes of Health (NIH) State-of-the-Science Panel

148. Hormone therapy for endometriosis and surgical menopause. (Abstract)

Hormone therapy for endometriosis and surgical menopause. Endometriosis is characterized by the presence of ectopic endometrial tissue that might lead to many distressing and debilitating symptoms. Despite available studies supporting standard hormone therapy for women with endometriosis and post-surgical menopause, there is still a concern that estrogens may induce a recurrence of the disease and its symptoms.This review aimed to look at pain and disease recurrence in women with endometriosis (...) recurrence or exacerbation of endometriosis This outcome was not reported in the first trial. The second found that 2/115 of the treatment group developed recurrence of endometriosis with no recurrence reported in the no-treatment group. This was not statistically significant. No woman was re-operated on in the no-treatment group compared with 2/115 in the treatment group.Hormone replacement therapy for women with endometriosis in post-surgical menopause could result in pain and disease recurrence

2009 Cochrane

149. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis

Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

150. Acupuncture for treating menopausal hot flushes: a systematic review

Acupuncture for treating menopausal hot flushes: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

151. Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review

Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

152. A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture

A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture A study to establish (...) the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture Stevenson MD, Oakley JE, Lloyd Jones M, Brennan A, Compston JE, McCloskey EV, Selby PL Citation Stevenson MD, Oakley JE, Lloyd Jones M, Brennan A, Compston JE, McCloskey EV, Selby PL. A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping

2009 Health Technology Assessment (HTA) Database.

153. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha

Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

154. Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK Full Text available with Trip Pro

Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK Lekander I, Borgstrom F, Strom O, Zethraeus N, Kanis JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of hormone replacement therapy (HRT) in women aged 50 years, who had menopausal symptoms, in comparison with no treatment. The authors concluded that HRT for women with menopausal symptoms was cost-effective. The methods were appropriate, but little information on the sources of the clinical and cost data was provided. The issue

2009 NHS Economic Evaluation Database.

155. Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany

Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

156. Medical care for menopausal and older women with HIV infection.

Medical care for menopausal and older women with HIV infection. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2008 New York State Department of Health

157. Herbal supplements did not relieve vasomotor symptoms of menopause in women

Herbal supplements did not relieve vasomotor symptoms of menopause in women Herbal supplements did not relieve vasomotor symptoms of menopause in women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Herbal supplements did not relieve vasomotor symptoms of menopause in women Article Text Therapeutics Herbal supplements did not relieve vasomotor symptoms of menopause in women Statistics from Altmetric.com Request Permissions If you

2008 Evidence-Based Medicine

158. Menopause. (Abstract)

Menopause. Menopause is the time of life when menstrual cycles cease, and is caused by reduced secretion of the ovarian hormones oestrogen and progesterone. Although menopause is a normal event for women, individual experiences vary, and some women seek medical advice for the management of symptoms. Many symptoms have been attributed to menopause, but only vasomotor dysfunction and vaginal dryness are consistently associated with this time of life in epidemiological studies. Other common (...) symptoms such as mood changes, sleep disturbances, urinary incontinence, cognitive changes, somatic complaints, sexual dysfunction, and reduced quality of life may be secondary to other symptoms, or related to other causes. Trials of therapies for vasomotor dysfunction have shown improvements with oestrogen, gabapentin, paroxetine, and clonidine, but little or no benefit with other agents; adverse effects of these treatments must also be considered. Many questions about menopausal transition and its

2008 Lancet

159. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. (Abstract)

Increased risk of parkinsonism in women who underwent oophorectomy before menopause. There is increasing laboratory evidence for a neuroprotective effect of estrogen on the nigrostriatal pathway; however, the epidemiologic evidence remains limited and conflicting. We studied the association of oophorectomy performed before the onset of menopause with the risk of subsequent parkinsonism.We included all women who underwent either unilateral or bilateral oophorectomy before the onset of menopause (...) -linkage system, and death certificates.Women who underwent either unilateral or bilateral oophorectomy before the onset of menopause had an increased risk of parkinsonism compared with referent women (HR 1.68; 95% CI 1.06 to 2.67; p = 0.03), and the risk increased with younger age at oophorectomy (test for linear trend; p = 0.01). The findings were similar regardless of the indication for the oophorectomy, and for unilateral or bilateral oophorectomy considered separately. The findings were also

2008 EvidenceUpdates

160. Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials

Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials Ma D F, Qin L Q, Wang P Y, Katoh R CRD summary The authors concluded that isoflavones significantly (...) reduced spine bone loss in menopausal women; effects were greater when more than 90mg/day of isoflavones was consumed and isoflavone was taken for six months. The evidence appears to support the authors’ conclusions, but the non significant results at 12 months were unexplained and may weaken the strength of evidence supporting the reported benefits of isoflavones. Authors' objectives To evaluate the effect of isoflavones on spinal bone mass in women. Searching MEDLINE (from 1966), EMBASE (from 1985

2008 DARE.